» Articles » PMID: 17308839

Auditory Monitoring in Ototoxicity

Overview
Date 2007 Feb 20
PMID 17308839
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Some pharmaceutical products are capable of damaging the human auditory system. Technological progress has provided numerous resources to monitor hearing but there still is some controversy regarding the selection of the most sensitive and specific tests.

Objective: to analyze audiological procedures used in the auditory monitoring of individuals exposed to ototoxic medication.

Methods: we searched the MEDLINE and LILACS literature databases, using terms pertinent to audiological monitoring, ototoxicity and cancer. The pertaining literature analysis identified two procedures often used worldwide for the early detection of auditory lesions induced by ototoxic pharmaceutical drugs: high-frequency audiometry and evoked otoacoustic emissions. Both allow early identification of hearing disorders before changes are seen in conventional pure-tone audiometry and, consequently, before speech understanding is compromised.

Conclusion: we suggest a hearing monitoring protocol, considering the patients capability to respond to behavioral tests and monitoring timing (first test/follow up). For cancer patients, hearing monitoring should be performed in the patients treatment venue.

Citing Articles

A longitudinal study of the peripheral and central auditory pathways in individuals with acute lymphoid leukemia.

Vosgrau J, Silva L, Filho V, Matas C Clinics (Sao Paulo). 2023; 78:100234.

PMID: 37356412 PMC: 10310478. DOI: 10.1016/j.clinsp.2023.100234.


Prevention and management of hearing loss in patients receiving ototoxic medications.

Lindeborg M, Jung D, Chan D, Mitnick C Bull World Health Organ. 2022; 100(12):789-796A.

PMID: 36466201 PMC: 9706352. DOI: 10.2471/BLT.21.286823.


Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies.

Ehlert K, Heinze B, Graham M, Swanepoel D J Laryngol Otol. 2022; 137(1):61-67.

PMID: 35611593 PMC: 9834705. DOI: 10.1017/S0022215122001281.


Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.

Shibeshi W, Sheth A, Admasu A, Berha A, Negash Z, Yimer G BMC Pharmacol Toxicol. 2019; 20(1):31.

PMID: 31122273 PMC: 6533713. DOI: 10.1186/s40360-019-0313-y.


A Review of Cisplatin-Associated Ototoxicity.

Paken J, Govender C, Pillay M, Sewram V Semin Hear. 2019; 40(2):108-121.

PMID: 31036989 PMC: 6486385. DOI: 10.1055/s-0039-1684041.